Aerie Pharmaceuticals Inc. filed for secondary offerings of $125 million of shares of its common stock this week, according to a Securities and Exchange Commission filing.

Of the offerings, $50 million was sold on Sept. 15. An additional $75 million in shares will be issued on or around Sept. 20 or Sept. 21.

Cantor Fitzgerald & Co. is acting as sole book runner for the $75 million public offering and sole manager for the $50 million program.

After it reported positive late-stage trial results for a glaucoma therapy called Roclatan, the company decided to raise the funds to run the corporation, complete funding for RhopressaTM commercialization costs, execute clinical trials in Japan, continue the construction of manufacturing plants abroad and continue preclinical activity to support its product pipeline.

The publicly traded clinical stage pharmaceutical company specializes in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other eye diseases.

The company’s research and development efforts are based in Durham.

Its shares closed Friday at $34.87, up $4.26 per share or 13.92 percent.

Note: This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism.